Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis

Ann Surg Oncol. 2024 Jun;31(6):3976-3977. doi: 10.1245/s10434-024-15264-2. Epub 2024 Apr 15.

Affiliations

¹ Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
² Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.
³ Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA. starlinger.patrick@mayo.edu.

PMID: 38619707
DOI: 10.1245/s10434-024-15264-2

No abstract available

Publication types

Comparative Study
Editorial
Letter

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use
Carcinoid Tumor / drug therapy
Carcinoid Tumor / pathology
Carcinoid Tumor / surgery
Humans
Intraoperative Complications
Malignant Carcinoid Syndrome / drug therapy
Malignant Carcinoid Syndrome / surgery
Octreotide* / therapeutic use
Prognosis
Vasoconstrictor Agents* / therapeutic use

Substances

Octreotide
Vasoconstrictor Agents
Antineoplastic Agents, Hormonal